journal article
Jul 01, 1999
Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients
Abstract
Abstract
Studies performed on airway smooth muscle in vitro have indicated that salmeterol is a partial agonist on the β2-receptor in comparison to formoterol. In the present study we evaluated whether these pharmacological differences between salmeterol and formoterol also are applicable to asthmatic patients. The protective effects by increasing cumulative doses of formoterol (12, 60, 120 μ g) and salmeterol (50, 250, 500 μ g) on methacholine-induced bronchoconstriction were evaluated in a double-blind, crossover, placebo-controlled design. Patients were regularly treated with salbutamol 200 μ g twice daily during the study period, to avoid variability in β2-adrenoceptor tolerance. S-potassium, heart rate corrected Q-T interval (Q-Tc), and tremor score were followed as measures of systemic effects. Formoterol dose-dependently protected against methacholine responsiveness (4.6 doubling doses after 120 μ g). Salmeterol, however, showed a flatter dose–response curve, and a significantly weaker maximal protective effect (2.8 doubling doses after 250 μ g). Formoterol caused a significantly higher tremor score and a larger drop in S-potassium than salmeterol at the highest doses. These data show that salmeterol is a partial agonist on the β2-receptor in relation to formoterol in human airways in vivo. Further studies are required to document the clinical consequences of this finding, for example in severe asthmatic patients.
Studies performed on airway smooth muscle in vitro have indicated that salmeterol is a partial agonist on the β2-receptor in comparison to formoterol. In the present study we evaluated whether these pharmacological differences between salmeterol and formoterol also are applicable to asthmatic patients. The protective effects by increasing cumulative doses of formoterol (12, 60, 120 μ g) and salmeterol (50, 250, 500 μ g) on methacholine-induced bronchoconstriction were evaluated in a double-blind, crossover, placebo-controlled design. Patients were regularly treated with salbutamol 200 μ g twice daily during the study period, to avoid variability in β2-adrenoceptor tolerance. S-potassium, heart rate corrected Q-T interval (Q-Tc), and tremor score were followed as measures of systemic effects. Formoterol dose-dependently protected against methacholine responsiveness (4.6 doubling doses after 120 μ g). Salmeterol, however, showed a flatter dose–response curve, and a significantly weaker maximal protective effect (2.8 doubling doses after 250 μ g). Formoterol caused a significantly higher tremor score and a larger drop in S-potassium than salmeterol at the highest doses. These data show that salmeterol is a partial agonist on the β2-receptor in relation to formoterol in human airways in vivo. Further studies are required to document the clinical consequences of this finding, for example in severe asthmatic patients.
Topics
No keywords indexed for this article. Browse by subject →
References
32
[1]
Arvidsson "Formoterol, a new long-acting bronchodilator for inhalation." Eur. Respir. J. (1989) 10.1183/09031936.93.02040325
[2]
Maesen "Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours." Chest (1990) 10.1378/chest.97.3.590
[3]
Ullman "Salmeterol, a new long-acting inhaled β2-adrenoceptor agonist: comparison with salbutamol in asthmatic patients." Thorax (1990)
[4]
[5]
Anderson "Why are long-acting beta-adrenoceptor agonists long acting?" Eur. Respir. J. (1994) 10.1183/09031936.94.07030569
[6]
Naline "Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus." Eur. Respir. J. (1994) 10.1183/09031936.94.07050914
[7]
Lindén "Salmeterol, formoterol, and salbutamol in the isolated guinea-pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism." Thorax (1993) 10.1136/thx.48.5.547
[8]
Palmqvist "Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency." Eur. Respir. J. (1997) 10.1183/09031936.97.10112489
[9]
van Noord "Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action." Eur. Respir. J. (1996) 10.1183/09031936.96.09081684
[10]
Jeppsson "Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro." Pharmacol. Toxicol. (1992) 10.1111/j.1600-0773.1992.tb00982.x
[11]
Källström "The interaction between salmeterol and β2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro." Br. J. Pharmacol. (1994) 10.1111/j.1476-5381.1994.tb17047.x
[12]
Ramsdale "Prolonged protection against methacholine-induced bronchoconstriction by the inhaled β2-agonist formoterol." Am. Rev. Respir. Dis. (1991) 10.1164/ajrccm/143.5_pt_1.998
[13]
Derom "The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours." J. Allergy Clin. Immunol. (1992) 10.1016/0091-6749(92)90435-5
[14]
Rabe "Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma." Am. Rev. Respir. Dis. (1993) 10.1164/ajrccm/147.6_pt_1.1436
[15]
[16]
Inman "The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs." J. Allergy Clin. Immunol. (1998) 10.1016/s0091-6749(98)70246-5
[17]
Bronchial reactivity to inhaled histamine: a method and clinical survey
D. W. Cockcroft, D. N. KILLIAN, J. J. A. MELLON et al.
Clinical & Experimental Allergy
1977
10.1111/j.1365-2222.1977.tb01448.x
[18]
Ryan "Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator and airway calibre." Thorax (1982) 10.1136/thx.37.6.423
[19]
Esmailpour "Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo." Eur. Respir. J. (1997) 10.1183/09031936.97.10071496
[20]
Lötvall "Measurement of airway hyperresponsiveness: new considerations." Thorax (1998) 10.1136/thx.53.5.419
[21]
Djukanovic "Effect of natural allergen exposure during the grass pollen season on inflammatory cells and asthma symptoms." Thorax (1996) 10.1136/thx.51.6.575
[22]
Boulet "Asthma and increases in non- allergic bronchial responsiveness from seasonal pollen exposure." J. Allergy Clin. Immunol. (1983) 10.1016/0091-6749(83)90069-6
[23]
Torphy "Functional antagonism in canine tracheal smooth muscle: inhibition by methacholine of the mechanical and biochemical responses to isoproterenol." J. Pharmacol. Exp. Ther. (1983) 10.1016/s0022-3565(25)22103-6
[24]
Cockroft "Regular inhaled salbutamol and airway responsiveness to allergen." Lancet (1993) 10.1016/0140-6736(93)92695-p
[25]
Cheung "Long-term effects of a long-acting β2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma." N. Engl. J. Med. (1992) 10.1056/nejm199210223271703
[26]
Booth "Salmeterol tachyphylaxis in steroid treated asthmatic subjects." Thorax (1996) 10.1136/thx.51.11.1100
[27]
Yates "Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment." Am. J. Respir. Crit. Care Med. (1995) 10.1164/ajrccm.152.4.7551366
[28]
Bhagat "Salbutamol- induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response." J. Allergy Clin. Immunol. (1996) 10.1016/s0091-6749(96)70282-8
[29]
Maesen "The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations." Chest (1991) 10.1378/chest.99.6.1367
[30]
Maconochie "Dose–response study with high-dose inhaled salmeterol in healthy subjects." Br. J. Clin. Pharm. (1992) 10.1111/j.1365-2125.1992.tb04049.x
[31]
Ulrik "Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic." Eur. Respir. J. (1994) 10.1183/09031936.94.07051003
[32]
Smyth "Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma." B.M.J. (1993)
Metrics
141
Citations
32
References
Details
- Published
- Jul 01, 1999
- Vol/Issue
- 160(1)
- Pages
- 244-249
- License
- View
Authors
Cite This Article
MONA PALMQVIST, THOMAS IBSEN, ANDERS MELLÉN, et al. (1999). Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients. American Review of Respiratory Disease, 160(1), 244-249. https://doi.org/10.1164/ajrccm.160.1.9901063
Related
You May Also Like
An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
David E. Griffith, Timothy Aksamit · 2007
5,099 citations
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
Jørgen Vestbo, SUZANNE S. HURD · 2013
3,831 citations
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
Romain A. Pauwels, A. SONIA BUIST · 2001
3,615 citations